This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ALK Announces An R&D And Business Briefing In NYC On 21 May

Copenhagen, May 1, 2014 (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) will host an R&D and business briefing for the investment community on Wednesday, 21 May in New York City. The meeting offers an opportunity to learn more about allergy immunotherapy and will highlight the recent advances and future potential for ALK's allergy immunotherapy business.

The agenda will introduce ALK as an emerging specialty pharmaceutical company with a global growth strategy, and will offer a broad introduction to allergy immunotherapy - a unique treatment of the underlying cause of allergic rhinitis and allergic asthma.

The meeting will focus on the growing opportunity for ALK's business in the US market following the recent FDA approvals for two sublingual allergy immunotherapy tablets, GRASTEK (r) and RAGWITEK (tm) , both licensed to Merck for commercialisation in North America. There will also be a dedicated session on the company's forthcoming sublingual allergy immunotherapy tablet for the most prevalent allergy in the world, house dust mite allergy.

The meeting will close with a look at opportunities in Japan and other international markets, as well as a summary of R&D efforts to globalise ALK's existing portfolio and to expand into treating allergic asthma.

The confirmed presenters include the international key opinion leader in allergy immunotherapy, Professor Moises Calderon, MD from Imperial College London, as well as key ALK executives:
  • Jens Bager: President and Chief Executive Officer
  • Henrik Jacobi: Executive Vice President, Research and Development
  • Soeren Niegel: Executive Vice President, Commercial Operations
  • Jose A. Moreno Toscano: President, ALK North America
  • Per Plotnikof: Head of Investor Relations and Strategic Planning

Jens Bager, ALK's President and CEO, said: "This meeting comes at an exciting time, following the FDA approvals for GRASTEK (r) and RAGWITEK (tm), the recent initiation of US Phase III trials for our house dust mite product, and positive results from a house dust mite Phase III trial in Japan. In addition, our newly announced collaboration with Eddingpharm in China illustrates that we are intent on further international expansion and growth. We look forward to telling you more about these developments and our plans for the future at our meeting in New York."

The meeting runs from 12.30-4.30pm and will be followed by an informal reception.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.64 -0.11%
FB $118.57 0.84%
GOOG $698.21 0.75%
TSLA $241.80 0.43%
YHOO $36.53 -0.19%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs